Stifel Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $10
Stifel has reiterated its Buy rating for Nkarta (NKTX.US) and maintained a target price of $10. This indicates a continued positive outlook from the firm regarding Nkarta's stock performance.
Stifel reiterates Buy rating on Nkarta stock, cites trial progress By Investing.com
Stifel reiterated a Buy rating and $10.00 price target for Nkarta Inc. (NASDAQ:NKTX) shares, following discussions with company executives about protocol amendments in the Ntrust-1/2 trials aimed at improving patient convenience and enrollment. Nkarta plans to present preliminary data from these trials at ACR Convergence in November, focusing on efficacy and safety in myositis and scleroderma patients. The company is also working on enhancing NKX019's efficacy, with more comprehensive updates expected in fiscal year 2027 to assess its competitiveness in autoimmune disease treatment.
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
Nkarta (NASDAQ:NKTX) plans to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology's 2026 Convergence meeting in November. The company is advancing outpatient CAR NK trials, with FDA-agreed protocol changes reducing observation periods and enabling broader access. Nkarta aims to prove CAR NK therapy's efficacy and safety, targeting a potential registrational study by late 2027.
Nkarta at stifel forum: safer cell therapy push gains traction By Investing.com
Nkarta Therapeutics presented at the Stifel 2026 Virtual Immunology and Inflammation Forum, detailing its strategy for a CD19-targeted CAR natural killer cell therapy in autoimmune diseases. The company highlighted FDA-approved protocol changes that have improved patient enrollment and convenience, emphasizing its off-the-shelf approach as a safer alternative to CAR T therapies, particularly for chronic autoimmune conditions. Nkarta plans to narrow its development focus to a few key indications and expects to present significant autoimmune data at the ACR Convergence 2026 meeting in November, with registrational trials potentially starting before the end of 2027.
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
Nkarta (NKTX) will present initial autoimmune clinical data for its investigational CAR-NK therapy NKX019 at ACR Convergence 2026 in Orlando. The company will deliver two oral presentations and one poster, covering the safety and clinical activity of NKX019 in idiopathic inflammatory myopathy, systemic sclerosis, and B-cell-mediated autoimmune diseases. These presentations mark an important milestone for Nkarta as they share their first overview of NKX019's safety profile and clinical activity.
Nkarta to Participate in September Investor Conferences
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company, announced its participation in two upcoming investor conferences in September 2026. The company will hold fireside chats at the H.C. Wainwright 28th Annual Global Investment Conference and the Stifel 2026 Virtual Immunology and Inflammation Forum. Webcasts of these events will be available on Nkarta's investor website.
Nkarta Insiders Got A Good Deal Selling At US$2.10
Nkarta, Inc. insiders may have missed out on recent stock gains after selling shares earlier in the year at US$2.07, below the current price of US$3.23. The CEO and Director, Paul Hastings, sold a significant portion of his stake, and while there has been insider selling, the amounts are considered small. The article notes low insider ownership and suggests caution, while also pointing out four warning signs for the company.
Nkarta to Participate in September Investor Conferences
Nkarta, Inc. announced its participation in two investor conferences in September 2026: the H.C. Wainwright 28th Annual Global Investment Conference and the Stifel 2026 Virtual Immunology and Inflammation Forum. The clinical-stage biopharmaceutical company will hold fireside chats at both events, with webcasts available on its investor relations website. Nkarta is focused on developing allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases.
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
Nkarta, Inc. announced its selection for three scientific presentations at ACR Convergence 2026, where it will present initial autoimmune clinical data for NKX019. Two oral presentations will highlight the safety of NKX019 across all autoimmune indications and its clinical activity in idiopathic inflammatory myopathy, while a poster presentation will detail its clinical activity in systemic sclerosis. This marks an important milestone for Nkarta as it shares the first overview of NKX019's safety profile and early efficacy in autoimmune conditions.
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
Nkarta, Inc. announced its selection for three scientific presentations at ACR Convergence 2026, highlighting initial autoimmune clinical data for its investigational CAR-NK cell therapy, NKX019. The presentations will cover the overall safety profile and clinical activity of NKX019 in idiopathic inflammatory myopathy and systemic sclerosis. This represents a significant milestone for Nkarta, showcasing the potential of NKX019 for broad patient access due to its tolerability, early efficacy, off-the-shelf availability, and outpatient dosing capability.
Monaco Asset Management SAM Makes New Investment in Nkarta, Inc. $NKTX
Monaco Asset Management SAM has acquired a new stake of 2.37 million shares in Nkarta, Inc. (NASDAQ:NKTX), valued at approximately $6.7 million, making it their 13th largest position and representing 3.32% of Nkarta. Despite Nkarta missing analyst expectations for its last quarterly earnings with a loss of $0.54 per share, institutional investors now own 80.54% of the company. Analyst sentiment remains a "Moderate Buy" with an average price target of $11.20, although some firms have lowered price objectives and earnings estimates due to projected continued losses.
Nkarta (NASDAQ:NKTX) Stock Rating Lowered by Wall Street Zen
Wall Street Zen has downgraded Nkarta (NASDAQ:NKTX) from a "sell" to a "strong sell" rating, despite a broader analyst consensus of "Moderate Buy" with an $11.20 target. Nkarta's shares opened at $2.33, near its 1-year low, and the company reported a quarterly loss of $0.54 per share, worse than estimates. Institutional investors hold a significant portion of the company's stock, and analysts project a full-year loss of $1.54 per share.
Stifel cuts Nkarta stock price target on updated model
Stifel has lowered its price target for Nkarta Inc. (NASDAQ:NKTX) from $11.00 to $10.00, while maintaining a Buy rating, following the company's Q2 2026 earnings and an updated model. The adjustment reflects ongoing patient enrollment progress in Nkarta's Ntrust-1/2 trials and upcoming preliminary data expected by year-end 2026. Despite the target cut, InvestingPro data suggests the stock may be undervalued, noting Nkarta's strong cash position but also its rapid cash burn, a common characteristic for clinical-stage biotech firms.
Stifel cuts Nkarta stock price target on updated model By Investing.com
Stifel has lowered its price target for Nkarta Inc. (NASDAQ:NKTX) to $10 from $11, while maintaining a Buy rating, following the company's Q2 2026 earnings and an updated financial model. The adjustment comes after discussions with Nkarta's management regarding patient enrollment progress in its Ntrust-1/2 trials and anticipated preliminary data by the end of 2026. Despite the price target cut, InvestingPro data suggests Nkarta may be undervalued, although the biotech company is noted for rapidly burning through cash, a common trait for firms in clinical development.
Stifel cuts Nkarta stock price target on updated model
Stifel lowered its price target on Nkarta Inc. (NASDAQ:NKTX) to $10.00 from $11.00, maintaining a Buy rating, following the company's Q2 2026 earnings and an updated model. The firm discussed patient enrollment progress in the Ntrust-1/2 trials and anticipates preliminary data by the end of 2026. Despite a strong balance sheet, Nkarta is rapidly burning cash, a common issue for biotechs in clinical development.
Stifel Nicolaus Has Lowered Expectations for Nkarta (NASDAQ:NKTX) Stock Price
Stifel Nicolaus has reduced its price target for Nkarta (NASDAQ:NKTX) from $11 to $10, while maintaining a "buy" rating, indicating a potential upside of 334.78% from the previous close. The company's shares opened at $2.30 and were down 3.8% after reporting a quarterly loss of $0.54 per share, missing analyst expectations. Despite mixed analyst sentiment, the consensus remains a "Moderate Buy" with an average target price of $11.20, and institutional investors hold a significant 80.54% stake in the company.
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
Nkarta, Inc. reported its second-quarter 2026 financial results, highlighting continued patient enrollment in its Ntrust-1 and Ntrust-2 clinical trials for NKX019 in autoimmune diseases, with initial data expected in 2026. The company's cash balance of $243.2 million as of June 30, 2026, is projected to fund operations into 2029. Nkarta emphasized expanding outpatient dosing through community-based sites, improving patient access to the NKX019 therapy.
Nkarta, Inc. Stock 12‑Month Price Target Cut to $11, Implies 347% Upside
Nkarta, Inc. (NKTX) has seen its average 12-month price target cut to $11 from $11.33 by analysts, with forecasts ranging from $9 to $14 per share. This updated target suggests a potential upside of approximately 347% based on the recent closing price. The consensus rating for the stock remains a "Buy" among the 8 covering analysts.
H.C. Wainwright cuts Nkarta stock price target on trial progress
H.C. Wainwright lowered its price target for Nkarta Inc. (NASDAQ:NKTX) to $14 from $16, while maintaining a Buy rating. The firm's decision followed Nkarta's Q2 2026 earnings report and an update on its Ntrust-1 and Ntrust-2 trials for NKX019 in autoimmune diseases, with initial data expected in late 2026. Despite strong liquidity, InvestingPro Tips indicate the company is rapidly burning cash.
NKARTA, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $14 FROM $16
H.C. Wainwright has revised its target price for NKARTA, INC. (NKTX.O) down to $14 from the previous $16. This adjustment reflects an analyst's updated valuation for the company. The article, sourced from Reuters, does not provide further details on the reasons behind the target price cut.
Nkarta, Inc. reports results for the quarter ended June 30 - Earnings Summary
Nkarta, Inc. has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters, states that unlimited access to the full content requires a TradingView subscription.
Nkarta (NASDAQ:NKTX) Posts Quarterly Earnings Results, Misses Estimates By $0.18 EPS
Nkarta (NASDAQ:NKTX) reported a quarterly loss of $0.54 per share, missing the consensus estimate by $0.18. Despite the earnings miss, NKTX shares rose 2.1% to $2.46 in midday trading. The company currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $10.75, and institutional investors own a significant portion of its stock.
Nkarta Q2 Results: Net loss widens to $40.4M, cash funds ops to 2029
Nkarta, a biotechnology company, reported a Q2 2026 net loss of $40.4 million, or $(0.54) per share, significantly missing analyst estimates and widening from the previous year. This increase is attributed to higher operating expenses, particularly in general and administrative costs. Despite the loss, the company holds $243.2 million in cash, projected to fund operations into 2029 as it advances its clinical trials for NKX019.
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
Nkarta, Inc. reported its second quarter 2026 financial results, highlighting continued enrollment in its Ntrust-1 and Ntrust-2 clinical trials for autoimmune diseases at the 4 billion cell dose level, with initial data expected in 2026. The company also announced that its cash balance of $243.2 million as of June 30, 2026, is expected to fund operations into 2029. Additionally, Nkarta has begun outpatient dosing of NKX019 through its expanding network of community-based sites following FDA agreement.
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Moderate Buy" by Analysts
Nkarta, Inc. (NASDAQ:NKTX) has received a consensus "Moderate Buy" rating from six brokerages, with an average 12-month price target of $10.75, significantly above its current share price of $2.41. The company reported a quarterly loss of $0.37 per share, beating analyst estimates. Institutional investors hold a substantial 80.54% of the company, and Nkarta is actively developing off-the-shelf CAR-NK cell therapies.
Nkarta Inc (NKTX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Nkarta Inc (NKTX) has an earnings forecast score of 8.67, ranking 75th in its industry. Analysts have set an average price target of $11.00, with a high of $16.00 and a low of $8.00, predominantly recommending a "Buy" for the stock. The company's EPS for the previous quarter met expectations at -$0.37, with the next quarter's EPS expected to be -$0.38.
Nkarta (NKTX) Projected to Post Quarterly Earnings on Tuesday
Nkarta (NKTX) is scheduled to report its Q2 2026 earnings before market open on Tuesday, August 11th, with analysts projecting a loss of $0.39 per share. The company previously exceeded estimates in Q1 by reporting a loss of $0.37 per share. NKTX shares are currently trading at $2.21, significantly below the consensus price target of $10.75, with institutional investors holding over 80% of the stock.
NKTX|Nkarta Inc|Price:2.090|Chg%:-0.060
This article provides a detailed stock analysis of Nkarta Inc (NKTX), highlighting its weak fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. It notes high institutional ownership and recent "Buy" ratings from analysts with a target price of $11.80. The analysis also covers the company's clinical-stage biopharmaceutical operations and its development of engineered natural killer (NK) cell therapies.
Nkarta Inc (NKTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Nkarta Inc (NKTX), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. The analysis suggests that NKTX is suitable for range-bound swing trading, with most indicators signaling "Sell" or "Oversold," and overall a "Neutral" signal based on combined technical analysis.
Nkarta, Inc. Revenue Breakdown – NASDAQ:NKTX
This article provides a brief overview of Nkarta, Inc. (NASDAQ: NKTX), focusing on its financial data and revenue breakdown. It points to the company's financials page on TradingView, indicating where users can find statements, statistics, dividends, earnings, and segment information. The content itself seems to be a placeholder or a partial scrape, as it primarily lists navigation elements and data sources rather than actual revenue breakdown details.
NKTX|Nkarta Inc|Price:2.115|Chg%:-0.105
This article provides a detailed financial summary of Nkarta Inc (NKTX), including its stock price, market capitalization, and various financial statements. It highlights key financial indicators such as EPS, Net Profit, Current Assets, Total Assets, Total Liabilities, Total Equity, Net Operating Income, Net Investment, and Net Financing, presenting both quarterly and annual data with year-on-year changes. The report also includes upcoming earnings information and answers frequently asked questions about Nkarta Inc's financial health.
Nkarta Inc (NKTX) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Nkarta Inc (NKTX), detailing its volatility, financial risks, and investment risks. It highlights the company's beta value of 0.92, indicating it tends to underperform in up markets but decline less in down markets. The assessment also includes various metrics such as VaR, maximum drawdown, realized volatility, and Sharpe Ratios over different periods, offering a comprehensive view of the stock's risk profile.
Nkarta Inc (NKTX) Institutional Confidence
Nkarta Inc (NKTX) has an institutional shareholding score of 7.00, placing it 80th out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 82.11%, a decrease of 4.32% quarter-over-quarter. James Simons is the largest institutional shareholder, holding 2.43% of outstanding shares.
Nkarta Inc (NKTX) Balance Sheet
This article provides the quarterly and annual balance sheets for Nkarta Inc (NKTX), detailing key financial metrics such as cash, assets, liabilities, and shareholders' equity. It allows investors to assess the company's financial health, analyze fundamentals, and calculate liquidity and leverage ratios. The data includes yearly and quarterly breakdowns for various financial components and answers frequently asked questions regarding NKTX's balance sheet.
Nkarta Market Sentiment
This article provides an overview of market sentiment for Nkarta (NKTX), including analyst consensus, short interest, options flow, and insider activity. The analysis indicates a "Buy" consensus from analysts, a 5.9% declining short float, and a bullish options flow. The piece also details recent analyst actions, including price target changes and rating adjustments.
Nkarta Inc (NKTX) Financial Health: Profitability & Balance Sheet Analysis
This article provides an analysis of Nkarta Inc's (NKTX) financial health, indicating a weak financial status and low operating efficiency. The company's financial score is 5.46, ranking 353 out of 386 in the Biotechnology & Medical Research industry, with critical data points like total revenue and operating profit not yet disclosed.
Nkarta Inc (NKTX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Nkarta Inc (NKTX), outlining both major shareholders and institutional holdings. It provides a breakdown of significant holders like RA Capital Management and New Enterprise Associates, along with the proportion of shares they own. The report also categorizes shareholders by type and presents a historical view of institutional shareholding and recent shareholder activity.
Nkarta Inc (NKTX) Cash Flow
This article provides a detailed quarterly and annual cash flow statement for Nkarta Inc (NKTX), covering operating, investing, and financing activities. It presents financial figures alongside year-over-year percentage changes, offering insight into the company's financial health and performance over time. The document also includes an FAQ section explaining key cash flow concepts and Nkarta Inc's recent figures.
Nkarta Inc (NKTX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Nkarta Inc (NKTX) has an earnings forecast score of 8.67, placing it 72nd in the Biotechnology & Medical Research industry. Analysts have a consensus "Buy" rating for NKTX, with an average price target of $11.00, suggesting a potential upside of over 400%. The company's EPS for the previous quarter met expectations at -$0.37, with the next quarter's EPS projected to be -$0.38, indicating continued analyst confidence despite upcoming losses.
Nkarta (NKTX) Stock Analysis Report | Financials & Insights
This report provides a financial analysis of Nkarta (NKTX), a clinical-stage biopharmaceutical company developing allogeneic NK cell therapies. It includes general company information, stock performance metrics, peer comparisons, and detailed financial statements (income statement, balance sheet, and cash flow) for recent fiscal years and the trailing twelve months. The analysis highlights that Nkarta has a negative Sharpe ratio over the past five years, indicating below-average risk-adjusted returns compared to peers.
Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11
Needham has reiterated its Buy rating for Nkarta (NKTX.US), maintaining a target price of $11. This indicates the firm's continued confidence in the company's prospects.
Nkarta at H.C. Wainwright cell therapy conference: autoimmune push By Investing.com
Nkarta (NKTX) presented its allogeneic CAR NK platform for autoimmune diseases at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. The company is focusing on B-cell-driven autoimmune diseases like lupus nephritis and rheumatoid arthritis, aiming for outpatient treatment and off-the-shelf manufacturing. A key data readout is expected in 2026, which will cover efficacy, dosing, and potential FDA guidance for their NKX019 program.
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Nkarta, Inc. announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. President Nadir Mahmood will present updates on the company's investigational CAR-NK cell therapy for autoimmune diseases in a fireside chat on June 30th at 2 p.m. ET. A webcast and replay will be available on Nkarta's investor section.
Price to sales forward of Nkarta, Inc. – NASDAQ:NKTX
This page displays the forward "Price to sales" metric for Nkarta, Inc. (NASDAQ: NKTX). The content is primarily a data placeholder, indicating the period, value, and change for this financial metric, but the actual numerical data is not provided in the extracted content.
Price to book forward of Nkarta, Inc. – NASDAQ:NKTX
The article "Price to book forward of Nkarta, Inc. – NASDAQ:NKTX" provides a snapshot of Nkarta, Inc.'s stock (NKTX) on the Nasdaq. It shows the company's financial data, specifically focusing on its price to book forward metric. The brief content indicates that the market was closed at the time, with no trades occurring.
Enterprise value to revenue forward of Nkarta, Inc. – NASDAQ:NKTX
This article provides financial information for Nkarta, Inc. (NASDAQ: NKTX), specifically focusing on its enterprise value to revenue forward. It appears to be a financial data page from TradingView, offering an overview of the company's financials, news, and other related market data.
Nkarta to present CAR-NK cell therapy updates a...
Nkarta, Inc., a clinical-stage biotech company, will present updates on its investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. President Nadir Mahmood will discuss the progress of their off-the-shelf NK cell therapies, which are designed for outpatient use. This presentation highlights Nkarta's efforts to broaden patient access to innovative autoimmune treatments.
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Nkarta, Inc. announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference, where its President, Nadir Mahmood, will discuss updates on the company’s investigational CAR-NK cell therapy for autoimmune diseases. The discussion will be available via webcast on Nkarta’s investor relations website. Nkarta is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf natural killer cell therapies.
Nkarta sets June 30 fireside chat on CAR-NK autoimmune therapy
Nkarta (Nasdaq: NKTX), a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. President Nadir Mahmood will host a fireside chat at 2 p.m. ET to discuss the company’s investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases. A webcast and replay will be available for approximately 90 days on Nkarta's investor website.
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Nkarta, Inc. announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference, where President Nadir Mahmood will share updates on the company's investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases. The fireside chat is scheduled for Tuesday, June 30th, at 2 p.m. ET, and will be webcast live with a replay available afterward. Nkarta is advancing allogeneic, off-the-shelf natural killer cell therapies for autoimmune diseases.
